Antiplatelet Drug Use in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes
- 1 January 2013
- journal article
- review article
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 125 (1) , 51-58
Abstract
Patients with unstable angina pectoris/non-ST-segment elevation myocardial infarction have an acute coronary syndrome. These patients should be treated with dual antiplatelet therapy with the use of aspirin plus either clopidogrel, prasugrel, or ticagrelor, depending on the clinical circumstances. Prasugrel must not be used in patients with a history of stroke or transient ischemic attack. If ticagrelor is used, the dose of aspirin must not be > 100 mg daily. Platelet glycoprotein IIb/IIIa inhibitors should not be used as part of triple antiplatelet therapy if there is an increased risk for bleeding or in non-high-risk patients, such as those with a normal baseline cardiac troponin level, those without diabetes, and those aged ≥ 75 years for whom potential benefit may be significantly offset by the potential risk for bleeding. Clinical trial data do not support the use of intravenous cangrelor or oral vorapaxar in the treatment of patients with acute coronary syndromes.Keywords
This publication has 46 references indexed in Scilit:
- Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary SyndromesNew England Journal of Medicine, 2012
- Effects ofCYP2C19Genotype on Outcomes of Clopidogrel TreatmentNew England Journal of Medicine, 2010
- Efficacy of High-Dose Clopidogrel Treatment (600 mg) Less Than Two Hours Before Percutaneous Coronary Intervention in Patients With Non–ST-Segment Elevation Acute Coronary SyndromesThe American Journal of Cardiology, 2010
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Prior aspirin use predicts worse outcomes in patients with non–ST-elevation acute coronary syndromes11This study was sponsored by COR Therapeutics Inc., South San Francisco, California; and Schering-Plough Research Institute, Kenilworth, New Jersey.The American Journal of Cardiology, 1999
- Effects of Prior Aspirin and Anti-Ischemic Therapy on Outcome of Patients With Unstable Angina 11This study was supported by Biogen, Inc., Cambridge, Massachusetts. Manuscript received July 28, 1997; revised manuscript received and accepted December 1, 1997.The American Journal of Cardiology, 1998
- A new clinical classification for hospital prognosis of unstable angina pectorisThe American Journal of Cardiology, 1995
- Aspirin, Heparin, or Both to Treat Acute Unstable AnginaNew England Journal of Medicine, 1988
- Aspirin, Sulfinpyrazone, or Both in Unstable AnginaNew England Journal of Medicine, 1985
- Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable AnginaNew England Journal of Medicine, 1983